Meeting
2021 ASCO Annual Meeting
Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.
Authors
Richard S.P. Huang
Foundation Medicine, Inc, Cambridge, MA
Richard S.P. Huang , Brennan Decker , Karthikeyan Murugesan , Matthew Hiemenz , Douglas A. Mata , Gerald Li , James Creeden , Shakti H. Ramkissoon , Jeffrey S. Ross
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2605)
DOI
10.1200/JCO.2021.39.15_suppl.2605
Abstract #
2605
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese patients with cancer.
First Author: Huangbin Lu
Poster
2022 ASCO Annual Meeting
Observer performance study to examine the feasibility of the AI-powered PD-L1 analyzer to assist pathologists’ assessment of PD-L1 expression using tumor proportion score in non–small cell lung cancer.
First Author: Seokhwi Kim
Poster
2022 ASCO Genitourinary Cancers Symposium
Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumor proportion score.
First Author: Matt D. Galsky
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.
First Author: Petros Grivas